Pacira BioSciences Inc. (PCRX) reported fourth-quarter 2025 results. Total revenue was $196.9 million, up 5.1% year-over-year, and gross profit was $156.6 million, up 6.3% year-over-year.
Balance sheet and other items of note:
Shares were down 2.61% since market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Pacira BioSciences Inc. Insider Trading Activity
Pacira BioSciences Inc. insiders have traded $PCRX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $PCRX stock by insiders over the last 6 months:
- SHAWN CROSS (Chief Financial Officer) has made 0 purchases and 3 sales selling 37,060 shares for an estimated $893,156.
- KRISTEN WILLIAMS (Chief Administrative Officer) sold 13,137 shares for an estimated $269,702
- LAUREN RIKER (Senior Vice President, Finance) has made 0 purchases and 2 sales selling 5,416 shares for an estimated $117,563.
- JONATHAN SLONIN (Chief Medical Officer) sold 3,960 shares for an estimated $95,396
- ABRAHAM CEESAY sold 2,354 shares for an estimated $64,005
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Pacira BioSciences Inc. Hedge Fund Activity
We have seen 129 institutional investors add shares of Pacira BioSciences Inc. stock to their portfolio, and 139 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. removed 939,092 shares (-49.8%) from their portfolio in Q4 2025, for an estimated $24,303,700
- POLAR CAPITAL HOLDINGS PLC removed 910,455 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $23,462,425
- CITADEL ADVISORS LLC added 748,590 shares (+1051.7%) to their portfolio in Q4 2025, for an estimated $19,373,509
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 482,105 shares (-73.9%) from their portfolio in Q4 2025, for an estimated $12,476,877
- ECOR1 CAPITAL, LLC removed 457,471 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $11,789,027
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 409,997 shares (+inf%) to their portfolio in Q3 2025, for an estimated $10,565,622
- VANGUARD GROUP INC removed 384,612 shares (-7.4%) from their portfolio in Q4 2025, for an estimated $9,953,758
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Pacira BioSciences Inc. Analyst Ratings
Wall Street analysts have issued reports on $PCRX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 01/09/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/09/2026
- Truist Securities issued a "Buy" rating on 11/07/2025
To track analyst ratings and price targets for Pacira BioSciences Inc., check out Quiver Quantitative's $PCRX forecast page.
Pacira BioSciences Inc. Price Targets
Multiple analysts have issued price targets for $PCRX recently. We have seen 4 analysts offer price targets for $PCRX in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Serge Belanger from Needham set a target price of $30.0 on 01/09/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $38.0 on 01/09/2026
- Glen Santangelo from Barclays set a target price of $27.0 on 12/09/2025
- Les Sulewski from Truist Securities set a target price of $28.0 on 11/07/2025
